Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibiotic combo tested in kidney patients

NCT ID NCT07104162

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 32 times

Summary

This early-stage study is testing an experimental antibiotic combination called Cefiderocol/Xeruborbactam in 40 people with different levels of kidney function. Researchers want to see how safe the drug is and how the body processes it after a single dose. The goal is to learn the right dose for patients with kidney impairment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Orlando Clinical Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact

    Contact

  • University of Miami Clinical Pharmacology

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cefiderocol/Xeruborbactam (an experimental antibiotic combination given through a vein)

What this could lead to

If successful, this study could help doctors understand how to safely dose this antibiotic in patients with kidney problems.

What could go wrong

This is a very early, small Phase 1 study focused on safety and drug levels, not on treating infections. It may not lead to a new treatment or may show unexpected side effects.

Conditions

The condition(s) this trial relates to.

bacterial infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.